General Information |
| Summary |
Since damaged articular cartilage does not regenerate spontaneously, current treatments rely on passive methods that focus on removing aggravating factors. The progressive degeneration and loss of articular cartilage are characteristic features of osteoarthritis. Even when surgically treating cartilage defects, regeneration often results in fibrocartilage rather than hyaline cartilage, which has the properties of healthy cartilage, making complete regeneration challenging.
Patients with osteoarthritis who experience persistent cartilage damage along with severe pain and loss of joint function often consider surgical treatment. In particular, for knee osteoarthritis, total knee arthroplasty (TKA) is commonly performed. However, due to the limited lifespan of artificial joints, TKA is not actively recommended for younger osteoarthritis patients.
Unlike existing transplantation-based treatments, MIUChon can be administered intra-articularly using a syringe in a clinical setting, reducing the surgical burden on patients and offering advantages as a non-surgical therapeutic option.
This research team aims to conduct a clinical study to evaluate the safety and exploratory efficacy of MIUChon, an induced pluripotent stem cell (iPSC)-derived chondrocyte aggregate, when administered to patients with osteoarthritis. |
| Clinical trials phase |
Not applicable |
| Start date (estimated) |
2025-04-17 |
| Clinical feature |
| Label |
Knee Osteoarthritis |
| Link |
http://purl.obolibrary.org/obo/NCIT_C215374 |
| Description |
Inflammation of the knee due to degeneration of the articular cartilage. |
|
Administrative Information |
| ICTRP weblink |
https://trialsearch.who.int/Trial2.aspx?TrialID=KCT0010313 |
| Other study identifiers |
| Name |
KCT0010313 |
| Description |
Clinical Research Information Service (CRiS), Republic of Korea |
|
| Source weblink |
https://cris.nih.go.kr/cris/search/detailSearchEn.do?seq=29067 |
| Regulatory body approval |
| Name |
Korean Ministry of Food and Drug Safety (MFDS) |
| Country |
|
|
| Study sites |
|
| Sponsors |
The Catholic University of Korea, Seoul St. Mary's Hospital
|
Cells |
| Which differentiated cell type is used |
| Label |
chondrocyte |
| Link |
http://purl.obolibrary.org/obo/CL_0000138 |
| Description |
Skeletogenic cell that is terminally differentiated, secretes an avascular, GAG-rich matrix, is embedded in cartilage tissue matrix, retains the ability to divide, and develops from a chondroblast cell. |
|
Recruitment |
| Recruitment Status |
Not yet recruiting |
| Estimated number of participants |
3 |
| Contact institutions/departments |
|
